乳化相关的分子亚型揭示了性结肠炎的免疫异质性和临床特征
Jinyang Zhai1, Runxi Fu2, Shangjian Luo1
1Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, PR China; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai, PR China.
Biochemical and biophysical research communications
|March 13, 2025
概括
研究人员在性结肠炎 (UC) 中确定了关键的乳酸相关基因 (LRG). 这些基因,包括MSN和MAPRE1,可以帮助诊断UC并预测治疗反应,提供个性化医疗潜力.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症状况,与结直肠癌和代谢问题有关.
- 在UC中注意到乳酸干扰,但乳酸和乳酸化在疾病发展中的作用尚未完全理解.
- 缺乏特定的生物标志物阻碍了研究这些过程在UC病变的研究.
研究的目的:
- 确定与性结肠炎 (UC) 相关的乳酸相关基因 (LRGs).
- 探索乳酸化在UC病变发生中的作用.
- 发现UC诊断和治疗预测的潜在生物标志物.
主要方法:
- 使用ConsensusClusterPlus和NMF进行基于LRG的UC亚型分类.
- 使用ssGSEA,xCell和CIBERSORT评估了免疫透.
- 采用WGCNA和拉索回归来识别基因模块和枢纽基因,在临床和临床前模型中进行验证.
主要成果:
- LRG有效地将UC患者与对照患者区分开来,并根据免疫透水平对其进行分层.
- MSN和MAPRE1被确定为关键的LRG,在UC中显著增加表达.
- 这些基因显示为UC和相关结直肠癌的诊断标记物,以及UC严重程度和治疗反应的预测因素.
结论:
- 高通量转录组数据揭示了枢纽LRG和UC中乳酸介导乳酸化的重要性.
- 在炎症状况中MSN和MAPRE1的上调强调了它们对个性化UC诊断和治疗的潜力.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
106
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
106
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
290
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
290
Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124


